New investment boosts Symcel’s development and rollout of rapid sterility testing solutions for advanced therapies

Stockholm, Sweden, 2025-05-28 - Symcel, a global leader in biocalorimetry, has secured SEK 80 million in new funding. The investment will accelerate the commercial rollout of Symcel’s biocalorimetric platform and support the continued development of transformative solutions for faster post-manufacture release of cell and gene therapies. The funding round is led by experienced life science investors, reflecting strong confidence in Symcel’s technology, team, and market potential.

Symcel CEO, Dr Jesper Ericsson commented: “We are developing groundbreaking technology and transformative solutions. Our early access systems and strategic sales have matured into collaborations with top leaders in our focus markets. This investment enables an acceleration of development and commercial activities with significant potential impact in several verticals, with a particular focus on rapid quality control solutions for Advanced Therapy Medicinal Products (ATMPs).”

Accelerating commercialization of rapid quality control testing of cell and gene therapies
Symcel’s proprietary biocalorimeter solutions enable real-time metabolic monitoring to detect microbial contamination significantly faster than traditional culture-based methods. Following key validation milestones, the solution is now positioned for broader commercial expansion. The calScreener™ is already in use at leading clinical institutions and therapy developers, with wider adoption expected across biopharmaceutical manufacturing workflows.

Strengthened leadership in biocalorimetry solutions
The investment empowers Symcel to further accelerate the development of current and new solutions based on the proprietary biocalorimeter technology. By broadening the platform’s capabilities, the company is positioned to address an even wider range of applications and product types. As demand increases for faster and more reliable analytical tools, Symcel will continue to invest in advancing its leadership in biocalorimetry — enabling broader adoption across pharmaceutical manufacturing, hospital GMP facilities, microbial R&D, clinical testing and contract development organizations.

Organizational expansion to support long-term growth
Symcel’s momentum is powered by a unique combination of internal expertise, strategic collaborations, and validation partnerships with early adopters. With the new funding, the company will accelerate commercial growth, development programs and the scaling of its organization. This enables Symcel to reach development milestones, offer closer collaboration, faster support, and product adaptations for customers integrating the technology into their workflows. 

Investor relations contact:
Hans Ericson, Chief Financial Officer
hans.ericsson@symcel.com

Media contact:
Per Lidén, Marketing Manager
per.liden@symcel.com